Teva Reports Strong Q1 2026 Results as PONLIMSI Biosimilar Receives FDA Approval and Olanzapine LAI Advances

Key Takeaways

• Teva’s biosimilar PONLIMSI received FDA approval across all indications of reference product Prolia (denosumab)
• Olanzapine LAI New Drug Application accepted by FDA for once-monthly schizophrenia treatment in adults
• Company preparing for Q4 2026 launch of olanzapine LAI with Phase 3 enrollment on target

---

Teva Pharmaceutical Industries delivered robust first-quarter 2026 financial results, bolstered by significant regulatory milestones including FDA approval of its denosumab biosimilar and advancement of its long-acting injectable antipsychotic.

Teva announced April 29, 2026, that its biosimilar PONLIMSI™ has received FDA approval across all indications of the reference product Prolia® (denosumab). The approval represents a major milestone for Teva’s biosimilar portfolio, potentially offering patients and healthcare systems a more cost-effective alternative to the osteoporosis treatment.

Pipeline Advances Drive Growth Strategy

The pharmaceutical giant also reported progress with its Xolair® (omalizumab) biosimilar candidate, which has been accepted for review by both the U.S. FDA and European Medicines Agency (EMA). This dual regulatory submission positions Teva to compete in the lucrative asthma and chronic urticaria treatment market.

In the neurology space, Teva’s olanzapine long-acting injectable (LAI) received NDA acceptance from the FDA in February 2026. The once-monthly treatment for schizophrenia in adults addresses a critical need for improved medication adherence in mental health care. Phase 3 enrollment remains on target, with the company preparing for a Q4 2026 commercial launch.

Market Position Strengthened

Teva’s generic portfolio continues contributing to revenue growth, including lenalidomide capsules, the generic version of Revlimid®. The company’s disciplined execution across both innovative and generic drug segments demonstrates its ability to navigate complex regulatory pathways while maintaining operational efficiency.

The strong Q1 performance reflects Teva’s strategic focus on high-value biosimilars and specialty medications. With multiple products advancing through regulatory review and approval processes, the company appears well-positioned to capture market share in key therapeutic areas including oncology, immunology, and psychiatry.

Analysts view these developments as validation of Teva’s portfolio diversification strategy, particularly given the competitive pressures facing generic drug manufacturers globally.

---

Frequently Asked Questions

What does PONLIMSI approval mean for patients?

PONLIMSI approval provides patients with a biosimilar alternative to Prolia for treating osteoporosis, potentially offering the same efficacy at a lower cost while increasing treatment access.

When will olanzapine LAI be available?

Teva is preparing to launch olanzapine LAI in Q4 2026, pending final FDA approval. The once-monthly injectable is designed to improve medication adherence for adults with schizophrenia.

How does this compare to existing schizophrenia treatments?

Olanzapine LAI offers once-monthly dosing compared to daily oral medications, potentially improving patient compliance and treatment outcomes while reducing the burden of daily medication management.

Related coverage

• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Vabysmo gains EU approval for retinal vein occlusion: what changes next